Introduction: Nanotechnology has provided new tools for addressing unmet clinical situations, especially in the oncology field. The development of smart nanocarriers able to deliver chemotherapeutic agents specifically to the diseased cells and to release them in a controlled way has offered a paramount advantage over conventional therapy.
INTRODUCTION
In the recent years the scientific community has devoted huge efforts in the search of novel treatments against unmet clinical situations such as inoperable cancers, degenerative pathologies or resistant infections, among others. The application of nanotechnology to medicine, the so called nanomedicine, has become a key discipline for the discovery of novel therapies against these terrible diseases. This discipline comprises the use of nanometric systems as drug delivery carriers, medical imaging or sensors for clinical diagnostics, [1] being the first application the most studied with around 76% of the research papers in nanotechnology published in 2014. The utilization of nanoparticles as drug carriers provides several advantages such as improved pharmacokinetic profile, possibility to employ lipophilic drugs, higher circulation time in comparison with the administration of the free drugs and lower toxicity as a consequence of the lower dosages employed in the nanovehicles. [2] In 1986, the Japanese researchers Maeda and Matsumura reported that macromolecules bigger than 40 KDa injected in the blood stream tended to accumulate preferably within tumoral tissues. They termed this phenomenon as enhanced permeation and retention (EPR effect). [3] This preliminary finding paved the way to the use of nanoparticles as drug delivery systems for antitumoral applications. [4] The reason for the accumulation of nanoparticles and big macromolecules into tumoral areas lies on the characteristic blood vessel architecture of tumoral tissues. Tumoral cells show a fast growing rate which requires high amounts of nutrients and oxygen. When the size of a tumoral mass exceeds 1 mm 3 the diffusion of the nutrients is not enough to support the accelerated metabolism of the tumoral cells and they begin to suffer starvation. Thus, they force the surrounding healthy cells to produce proangiogenic factors which induce the creation of novel blood vessels. However, these novel vessels are not properly built, but they present pores and fenestrations with diameters up to a few hundreds of nanometers. [5] When the nanocarriers reach the tumoral tissue, they are able to pass through these fenestrations whereas they cannot pass through blood vessel epithelium present in healthy tissues. Additionally, the rapid growing rate of the tumoral cells usually compresses the lymphatic vessels compromising their normal function, which causes an inefficient drainage in the zone. The lack of a drainage system induces a higher retention of the nanoparticles extravasated in the tumoral mass. These two characteristics, higher permeability of the tumoral blood vessels (enhanced permeation) and lack of efficient lymphatic systems (enhanced retention) explain the preferential accumulation of the nanocarriers within the tumoral lesion. Almost 30 years later, a countless number of drug delivery nanosystems have been reported for oncological applications and even some of them have reached the market.[6] These nanocarriers can be formed by organic materials resulting in soft systems such as liposomes, polymersomes and micelles, among others, or can exhibit an inorganic nature originating tougher systems such as metallic or ceramic nanoparticles. [7] However, the use of pure inorganic materials in nanomedicine is strongly limited and it usually requires the creation of hybrid materials which conjugate the advantages of both type of systems. [8] Among the different materials that have been employed to build these hybrid nanocarriers, those systems which present ordered porosity constitute excellent materials for drug delivery applications due to their unique characteristics such as high loading capacity, chemical and physical robustness, low toxicity and easy and cheap production in the laboratory. The presence of the pore network increases considerably the available surface in comparison with solid counterparts. These pores can be engineered with a broad range of diameters, from 2 to a few tens of nanometers allowing the transportation of therapeutic agents with very different nature, such as small drugs, proteins, DNA or RNA strands and even other nanoparticles. Moreover, the ordered porosity of these materials allows more precise control over the drug cargo/departure process and also in the own material biodegradation. In this review, the recent advances carried out in the application of porous inorganic and metal-organic materials in drug delivery will be presented paying special attention to the application of mesoporous silica, porous silicon and metal-organic nanoparticles in antitumoral applications. For the synthesis of these materials, the reader could be referred to some excellent reviews. [9, 10] Additionally, detailed descriptions of the different functionalization strategies for the decoration of nanomaterials with different (bio)moieties can be found elsewhere. [11] 
MESOPOROUS SILICA NANOPARTICLES
Mesoporous silica nanoparticles (MSNs), specially presenting the MCM-41 structure, is a very promising material for drug delivery applications thanks to their specific properties. These nanoparticles can be easily obtained in the laboratory showing a wide range of morphologies, particle size and pore diameters. [12] MSNs presents high loading capacity (600-1000 m 2 ·g -1 ), high pore volume (0.6-1 mL·g -1 ) and pore size between 2-5 nm. This last property allows the loading of species with very different nature, from small molecules to macromolecules such as proteins or DNA which can reach sizes of around a few dozens of nanometers. Additionally, the external and/or internal surface of these particles can be decorated with different functional groups such as amino, thiol or carboxylic groups, among others, using the correspondently functionalized alcoxysilanes through direct addition in one pot (co-condensation) or after the particle formation (post-synthesis). When a nanocarrier is employed for oncological applications, it is particularly important to avoid the premature release of the housed drugs due to the highly toxic nature which usually present these therapeutic agents. In the case of MSNs, it is possible to avoid the unwanted drug departure employing two different strategies. The first one consists in the attachment of different moieties (gatekeepers) on the pore outlets through covalent bonds which can be broken by an externally applied stimulus (light, magnetic fields, ultrasounds or temperature) or by an internal stimulus inherent to the treated pathology (acid or basic environments, change in redox conditions, presence of enzymes, etc.) [13] The second strategy for controlling the drug release consists in the coating of MSN surface with polymeric or lipidic shells which hampers the diffusion of the drugs trapped within the silica network. [14] These polymeric or lipid coatings are engineered to allow the drug release due to conformational changes in the polymeric layer once exposed to certain stimuli (Figure 1). In this section, the recent advances in the development of these stimuliresponsive materials carried out in the latest years will be briefly described. Due to the huge number of stimuli-responsive MSNs which have been reported, these devices will be separately described according to the stimulus employed for triggering the release. A more exhaustive description of this field has been reviewed elsewhere. [15] 
Light
Light irradiation as triggering stimulus provides a precise control of the drug release location, being possible to apply the light beam in sub-millimetric regions.
Contrariwise, its main liability is poor penetration in living tissues. Only light with wavelength located in the near infrared (NIR) window (650-1350 nm) is able to penetrate a few dozens of millimeters into a tissue. UV and, to a lesser extent, visible light, are strongly absorbed by living tissues and their use is limited to exposed or transparent regions. After the pioneering work of Fujiwara et al. who described the attachment of coumarin molecules on the pore entrances as UV-cleavable gatekeepers, [16] many different responsive MSNs which are triggered by UV light have been described. [17] Despite the poor penetration of UV light, the application of these devices could be possible for the treatment of exposed lesions such as skin, esophagus or colon tumors, or the light can be delivered to the target zone using a optic fiber. Lu et al. have reported the use of polymeric coatings on the surface of hollow MSN which can be degraded by the irradiation with green light (540 nm). [18] Additionally, folic acid was conjugated to the polymer branches in order to provide selectivity against tumoral cells which overexpress folate receptors showing excellent antitumoral response only under light irradiation. A modified azobenzene molecule able to suffer photoisomerization with red light (625 nm), which is more penetrating in living tissues, has been recently reported as light-sensitive gatekeeper. [19] The group of Thomas Bein has widely studied the attachment of photosensitizers (as protoporphyrin IX) on MSN surface in order to induce endosomal escape of these carriers when exposed to radiation at 405 nm. [20] Nearly all the nanocarriers that are internalized by mammalian cells are uptaken via endocytosis. Therefore, to achieve rapid escape from the endosomes is of paramount importance for intracellular drug delivery in order to avoid the degradation of the transported molecules within late endosomes or lysosomes. Gold nanorods have been encapsulated within MSNs for inducing temperature increases in the surroundings after NIR exposition due to plasmonic photothermal conversion. Thus, Yang et al.
employed calix [4] arenes which binds by supramolecular interactions quaternary ammonia groups placed on MSN that contains gold nanorods. [21] NIR irradiation produces hyperthermia in the region which reduces the binding affinity of the calix [4] arenes by the ammonia stalks causing the dissociation of these gatekeepers and the subsequent drug departure. Drug-loaded MSNs have been anchored on the surface of single-walled carbon nanotubes (SWNT) in order to combine the high loading capacity of MSN with the ability to transform NIR into thermal energy of SWNT. [22] This hybrid device is able to accumulate into tumoral lesions in a mice model and once there, to release its payload under NIR exposition acting simultaneously as contrast agent for photoacoustic imaging. Other approaches which exploit NIR-to-visible upconversion phenomena [23] and even X-rays [24] have been recently reported providing more strategies to the use of light as triggering stimulus.
Temperature, magnetic field and ultrasounds
There are different pathological conditions which are associated with a temperature increase. A general approach to achieve temperature-responsive behavior consists in coating the external surface of MSN with thermosensitive polymers, mainly based in poly(N-isopropylacrylamide) (PNIPAM). This polymer suffers a conformational change from linear to globular state when the temperature exceeds 32 o C. A polymeric shell placed on the external surface of MSNs act as a diffusion barrier which avoids premature release of the housed drugs when the temperature is kept below this value.
However, if the temperature is higher, the polymer shell collapses and the retained drugs are able to escape from the silica matrix. This transition temperature is not useful for in vivo applications but it can be tuned to higher values between 40-45 o C adding hydrophilic monomers such as acrylamide, acrylic acid or N-hydroxymethylacrylamide to the polymer composition. Significant temperature increases can be achieved under alternative magnetic fields exposition of MSNs containing superparamagnetic iron oxide nanoparticles (SPIONs) trapped inside. Zink et al. have reported that the temperature of the particle surroundings can be increased almost 20 ºC after a short time magnetic field exposition, depending on the size of the SPIONs trapped within the silica matrix. [25] Thus, different engineered polymer coatings have been employed in combination with magnetic MSNs in order to control the release of both drugs trapped inside the pore network [26] and also higher macromolecules trapped within the polymer branches. [27] Moreover, magnetic MSN have been coated with lipid bilayers which are spontaneously disrupted at high temperatures. [28] Finally, DNA or peptide motifs have also been used as temperature responsive gatekeepers. [29] Recently, Paris et al. have described the use of ultrasounds as triggering stimulus for drug release. [30] In this case, MSN surface was coated with a thermosensitive polymer which contains 2-tetrahydropyranyl methacrylate (THPMA) as monomer sensitive to ultrasounds. This polymer collapses at physiological temperature (37 ºC) sealing the pore entrances, thus avoiding drug leakage. Under ultrasound irradiation, the acetal group of THPMA is broken enhancing the hydrophillicity of the polymer shell which places the transition temperature above this temperature and therefore, produces the pore opening.
pH
A nanoparticle which is travelling through the body will experience significant pH variations, from neutral pH in the blood stream to mild acidic conditions (pH 5.5-6) in tumoral, inflamed and infected tissues. Additionally, the pH inside the cells is generally more acidic than the pH present in the intracellular media, especially in endosomes and lysosomes. Therefore, it is possible to exploit this fact in order to design nanocarriers able to release their payloads when they reach these intracellular organelles. One well established strategy to synthesize pH-sensitive MSN is to coat the MSN external surface with polymers which present neutral charge at physiological pH, whereas they become positively charged under mild-acidic conditions. [31] The dense polymer layer hampers the drug release at neutral pH but if pH drops to certain values, the repulsion forces exerted between charged chains distort the polymer layer allowing the drug departure.
Another approach is the use of pore blockers which are attached on the pore outlets through sensitive bonds which are broken at mild-acidic conditions. Cai et al. have recently reported the development of hollow MSNs which exhibit a cascade process triggered by pH. [32] The particle surface is functionalized with beta-cyclodextrins (β-CDs) through boronate bonds. β-CDs bind to adamantane groups attached to PEG chains through imine bonds producing the pore closure. When the particle reaches the tumoral area (pH = 6.8), the imine bonds are broken causing the PEG detachment which 
Redox
The intracellular media is enriched in reductive species such as glutathione (GSH) in comparison with the extracellular environment. One approach to exploit this imbalance for triggering drug release is to attach polymers or pore blockers on the particle surface using dithiol bonds (S-S) which are broken by the presence of GSH. [37] Additionally, the polymer itself can be formed using redox-sensitive monomers or crosslinkers. [38] Shi et al. have synthesized hollow MSNs with large pores (24 nm of diameter, average) decorated with poly (β-amino esters) through dithiol bonds in order to deliver, in a redox responsive manner, siRNA and doxorubicin, simultaneously. [39] Kim et al. have described the use of specific Fmoc-functionalized peptide chains which contain a S-S bond as redox-sensitive pore blocker. [40] These peptides adopt a specific turn-like conformation when attached on the pore entrance, avoiding the drug release. The addition of GSH produces a conformational change to a random structure allowing the retained drug to leak out from the particle. Finally, in a very recent work, De Cola et al.
have reported a very interesting approach which consists in the preparation of MSNs containing breakable S-S-bonds within the silica framework in such a way that they are able to undergo accelerated degradation when exposed to the reductive intracellular media. [41] 
Macro-and small-molecules
There are different pathologies in which certain enzymes or molecules are produced more abundantly than in the healthy state. In the case of oncology, tumoral cells of solid tumors usually overexpress proteolytic enzymes as metalloproteinases (MMP) or cathepsins in order to degrade the extracellular matrix and colonize other tissues. Avidin has been anchored on MSN surface by a biotynilated peptide chain which contains a sequence sensitive to MMP-9. [42] This device has been able to deliver two therapeutic agents (cisplatin and proteasome inhibitor bortezomib) specifically to tumoral cells in ex vivo 3D lung tissue cultures without affecting the healthy cells also present in the tumoral mass. Zhu et al. have recently described a very interesting MSN device able to release its payload in the presence of micro-RNA (miR-21) which is overexpressed by several tumoral cells. [43] This system is composed by MSN which contains quantum dots housed within the silica matrix in order to allow its traceability by fluorescence microscopy. The external surface is decorated with specific DNA strands which bind, by complementarity, hybrid DNA strands which contain the anti-miR-21 sequence and the AS1411 aptamer, this last in charge of the recognition of the tumoral cells. This hybrid structure acts as reversible pore blocker and targeting agent at the same time and it can be uncapped by the exposition to miR-21. Additionally, the presence or the higher concentration of small molecules or ions in pathological tissues can be exploited for triggering drug release. Au nanoparticles, as removable caps, have been anchored to the pore outlets using Cu 2+ complexes as binding ion. [44] These copper complexes are broken at low pH values (< 5) and also in the presence of higher concentration of ATP (> 4mM). PSiNP. [52] The positive charge of this polymer promotes its adhesion by electrostatic interactions on the negatively charged particle surface. Additionally, the resulting particle presents a positive surface which facilitates the interaction with cell membranes and therefore, the particle uptake. In the case of naked particles, the retained oligonucleotides are rapidly released (80% of the cargo is released in the first 4 hours)
POROUS SILICON NANOPARTICLES
whereas it requires more than 35 hours when the particles are coated.
PSiNP can be loaded with two or more species, even with molecules which present very different nature, in order to combine several therapeutic effects, or to beat the acquired drug resistance of tumoral cells (Figure 3) .
Thus, indomethacin, a hydrophobic anti-inflammatory drug and hydrophilic peptides as PYY3-36, a 36 aminoacids peptide that inhibit the appetite, were effectively loaded within PSiNP showing acceleration in their release profile and higher drug permeation in tissue models as a consequence of their mutual influence. [53] In other recent work, methotrexate, a folic acid analog which is used as antitumoral drug was chemically grafted on amino-functionalized PSiNP walls and sorafenib, an anti-angiogenic hydrophobic drug, was loaded within the pore network. This polymer shell provides several interesting advantages such as increased colloidal stability caused by electrostatic repulsion between the particles, endosomal escape as a consequence of proton sponge effect originated by the presence of tertiary amines in PEI and finally, a sustained drug release behavior due to the polymer coating. [56] Finally, similarly to the case of MSN although much less exploited, different stimuliresponsive gatekeepers can be anchored on the pore outlets in order to control drug departure. Thus, cyclodextrins have been anchored on the pore entrances using supramolecular interactions which can be broken at mild acidic conditions. [57] pHsensitive polymers as poly(beta-amino esters) have also been employed as gate-keepers in this type of material. [58] 
METAL-ORGANIC FRAMEWORKS (MOFs)
Coordination polymers (CPs) have emerged as a novel family of nanostructured materials for encapsulation and drug release applications over the last years. [59] Advantages, if properly addressed, are multifold: On the contrary, NMOFs exhibit tunable pores with an exceptionally high surface area and high loading capacities. [65] Their geometries, size, and functionalities can be systematically varied to yield architecturally robust porous structures with a typical porosity up to 50% of the crystal volume. These materials exhibit a wide range in pore diameter between 2-50 nm, similarly to the materials described above. Accordingly surface areas can range from 1000 to 10,000 m 2 /g, much higher than those of other traditional porous materials such as zeolites and carbons. Therefore An enjoyable example of the advantages of drug encapsulation was given by Gref at el.
Single reports of small drugs
[76] These authors encapsulated the highly hydrophilic prodrug phosphated gemcitabin (Gem-MP), known for its instability and inability to bypass cell membranes, within MIL-100 NMOFs. Interestingly, the storage stability of the loaded NMOFs was strongly dependent on the media; indeed, while the NMOF turns out to be stable in water at least for three days significant release was found in media containing phosphates since it induces its particle degradation. Moreover, the drug-loaded NMOFs were effective against pancreatic PANC-1 cells in contrast to free drug and empty NMOFs, which apparently did not show any cytotoxic effect. 
Encapsulation and controlled release of most common drugs

Camptothecin and Doxorubicin
In a recent work crystals of the well-known ZIF-8 were loaded with Doxorubicin (DOX) and used as efficient drug delivery carriers with efficacies on breast cancer cell lines remarkably higher than those found for free DOX. 
5-Fluorouracil
This is without any doubt one of the antitumoral drugs most widely loaded within Multifunctionality has also been reported with other systems beyond NO. For example, Lin and co-workers reported the first use of NMOFs for the combined delivery of cisplatin and pooled siRNA. [99] For this, cisplatin and a pool of siRNAs targeting multidrug resistant genes were loaded into UiO hexagonal plate like NMOFs with ∼100 nm diameter and ∼30 nm thickness with high loading amounts. Interestingly, these systems efficiently delivered both siRNA and cisplatin to four cisplatin-resistant human ovarian cancer cells (ES-2, OVCAR-3, SKOV-3 and A2780/CDDP) decreasing the cisplatin IC50 values by an order of magnitude as compared to free cisplatin. This efficacy increase was attributed to the activation of the drug resistant gene from the ovarian cancer cells to cisplatin mediated by siRNA/UiO-Cis NMOFs.
CONCLUSIONS
Even though porous materials are still far from becoming a real and widely approved solution for drug delivery into the market, these materials have already
shown their versatility and efficiency in many crucial areas of relevance, from high yield encapsulation to targeted cytotoxicity. Comparatively, most of the work has been done on mesoporous silica nanoparticles by comparison with the two other approximations having some prototypes in clinical trials.
First reports on the use of PSiNP and NMOFs for antitumoral applications were described less than a decade ago but since then the number of citations and papers being reported in the area is increasing exponentially. Much of the work so far devoted is focussed on fundamental concepts of increasing loading encapsulation yields, surface functionalization and the interaction of drug with different carriers. Though, work in the near future should be concentrated more on their colloidal stability, permeability and drug release responses in real biological environments.
EXPERT OPINION
General Comments
Porous nanoparticles constitute one of the most promising materials for clinical use in the treatment of cancer. Advantages are multifold: I) they exhibit a great loading capacity clearly higher than the capacity shown by other organic systems as polymersomes, micelles, liposomes, or definitely over non-porous inorganic materials, compartments linked together to operate separately, yet function synergistically; (ii) dexterity to carry out parallel operations; (iii) ability to count, sort, and code information; and (iv)capability of dynamics with high fidelity.
Size and shape
Another area of relevance is that of the final dimensions of the nanostructures. Indeed, the collapse of lymphatic vessels within a tumor facilitates the retention of extravasated nanoparticles in the tumoral area; nevertheless, this also causes the apparition of interstitial fluid pressure which strongly hampers their diffusion within the zone.
Therefore, the action of these nanomedicines is restricted to the periphery of the tumors which drastically reduces their therapeutic efficacy. As a general rule to overcome this limitation, smaller sizes of nanocarrier achieve deeper penetrations. However, higher sizes yield better discrimination between healthy and tumoral tissues. Therefore, it is necessary to optimize the size carrier for each type of tumor. MSNs can be easily prepared with a wide range a shapes, sizes and external functionalization. [12] The influence of these parameters in cell uptake processes have been widely studied showing that the aspect ratio and surface charge play an important role in cell internalization and this process is highly cell dependent. [100] Additionally, in the case of intravenous administration (that is the usual case for antitumoral therapy) it is necessary to take into account the influence of these parameters in the interaction of the nanocarriers with the blood cells. However, in most cases these parameters have been evaluated using simplistic in vitro models and much work is required in order to know their significance in animal models. NMOFs with good dimensions between tens of nanometers and a few hundred nanometers have been reported though with some irregular shapes in some cases, plate-like structures or not perfectly round-shaped nanoparticles. Therefore detailed studies about the effect of the shape would be required. Another limitation of nanocarrier diffusion is caused by the high collagen density present in tumoral tissues. In order to improve the diffusion, proteolytic enzymes have been administered a few days before nanoparticle administration, or even these enzymes have been anchored on the particle surface. [36] In the case of porous nanoparticles, their lack of flexibility may difficult even more the penetration in living tissues and the barriers mentioned above play an even more important role. Thus, it is compulsory to take into account these barriers in order to design a suitable nanocarrier for future developments.
Surface functionalization
Another area of relevance lies at the surface functionalization of the nanoparticles and their effect on their improved stabilities and cell internalization. Indeed, one of the main advantages of nanoparticles as drug carriers for oncological applications is their passive accumulation within tumoral lesions by EPR effect. Once there, the presence of targeting agents attached on the particle surface enhances their uptake in these diseased cells, without affecting the healthy ones which are also present in the tissue. This fact allows the selective destruction of malignant cells. However, despite the good outcomes observed in in vitro experiments, only a few targeted nanodevices have demonstrated good performance in animal models. There are several reasons which contribute to this failure. One of them is that when a nanocarrier comes into contact with blood, it is immediately covered by a protein layer called protein corona. This corona masks the targeting agents which are the real readable part of the nanocarrier. Thus, the fate of the nanocarrier is not ruled by the presence of the targeting agents on the surface but it depends on the proteins bound to the particle surface. Additionally, the presence of the protein corona usually accelerates the particle clearance by the mononuclear phagocytic system (MPS). These limitations can be alleviated grafting the targeting agents employing hydrophilic or zwitterionic polymers as spacers. These polymers avoid protein adsorption enhancing the circulating time and they also present more effectively the targeting agents to tumoral cell receptors. Another issue which limits the in vivo nanocarrier performance is the high complexity and heterogeneity of the tumoral mass which not only present several types of tumoral cells but it also contains a huge number of non-tumoral cells as mesenchymal, immune, supportive cells, etc. which play an important role in tumor progression. In many cases, the efficacy of targeted nanodevices is tested employing simplified in vitro models which contain only the tumoral cell. It is true that in vitro models provides valuable information about the recognition process between the targeting agent and the specific tumoral cell receptor but, before reaching in vivo evaluation, it should be necessary to evaluate this capacity employing more realistic models such as 3D tissue models or tumor spheroids which contains a representative mixture of tumoral and non-tumoral cells, as well as cells from the immune systems. Finally, another drawback associated with the use of targeted nanomedicines is the binding site barrier, which is caused by the strong affinity between the targeting moiety and its receptor. This fact provokes that nanomedicines are firmly bound to the first cell line near tumoral blood vessels exacerbating even more the poor penetration problem mentioned above. One way to reduce this effect is to employ stimuli-responsive targeting agents which travel through the body in a hidden conformation, whereas they can be activated by certain stimulus present in the tumoral area or externally applied. [101] Great success has been achieved on the surface functionalization of silica nanoparticles. A high number of synthetic strategies for the decoration of the external surface of MSN and PSiNP have been described. It is even possible to functionalize differently the external surface and inner pore walls. However, in many cases it is necessary to achieve a precise control of the orientation of the grafted biomolecule, as in the case of antibodies or other recognition moieties. In this sense, it would be very useful to employ the wide arsenal of synthetic alternatives which provides the bioorthogonal chemistry. [102] Once more, surface functionalization is less common for NMOFs most of the times limited to the reactivity of some metal ions lying at the surface of the nanostructures or mainly to some polymeric or lipidic coatings.
Another limitation, not only for porous nanoparticles but common to several nanocarriers, lies in the fact that passive accumulation by EPR effect is not always guaranteed because this phenomenon is not universal. It not only depends on the tumor type but it also exhibits great heterogeneity within one tumoral lesion. Additionally, EPR undergoes variations during the treatment. Thus, tumors which exhibit a significant EPR effect at the beginning of the treatment could show scarce passive accumulation after some cycles of treatment. Therefore, it is necessary to monitor the vascular architecture of the tumoral lesion before recommending a treatment based on nanomedicines. It is possible to enhance the EPR effect through the previous administration of drugs as angiotensin I-converting enzyme (ACE) inhibitors or NO releasing agents. [4] It is important to keep in mind that the design of a nanocarrier able to overcome all of these barriers would be pointless, because it would require to build really complex systems, difficult to approve by regulatory agencies.
[103] The administration of diverse types of nanocarriers, each of them responsible for different tasks, could be simpler and more efficient than the design of one single carrier able to perform all of them. There are a few examples of cooperative work between nanoparticles in which, for example one of them facilitates the extravasation of the second one in the tumoral area,[104] but more efforts are needed in this point. As was pointed out above, there are many parameters which affect the efficacy of these types of nanocarriers and more knowledge is needed in order to find solutions for them. For the design of the next generation of novel porous inorganic nanocarriers we have to bear in mind the well-known quote in the engineering world "embrace complexity, design versatility and deliver simplicity". 
